Shots:

• Chimerix to receive $5M up front- up to $150M as clinical- regulatory & commercial milestone with royalties on global sales of Brincidofovir. SymBio to get exclusive WW rights to develop- manufacture & commercialize Brincidofovir in all human indications excluding prevention and treatment of smallpox and is responsible for all development- manufacturing & commercialization activities
• The collaboration will allow Chimerix to focus on the development of Dociparstat sodium (CX-01) in a P-III study as a 1L treatment for AML and provide an opportunity to participate in the value of ongoing development of Brincidofovir through milestones & royalties
• Chimerix’s Brincidofovir (BCV- CMX001) is an anti-viral therapy being developed for the treatment of cytomegalovirus- adenovirus- smallpox- and ebolavirus infections and is a prodrug of cidofovir

Click here to­ read full press release/ article | Ref: Chimerix | Image: Pappas Capital